Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY: PFE )

26.18 +0.53 (+2.07%)
Streaming Delayed Price Updated: 3:58 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,095,155
Open 25.75
Bid (Size) 26.18 (166)
Ask (Size) 26.19 (603)
Prev. Close 25.65
Today's Range 25.74 - 26.45
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel. 
Via Investor's Business Daily

Performance

YTD
-11.94%
-11.94%
1 Month
-7.98%
-7.98%
3 Month
-9.47%
-9.47%
6 Month
-7.49%
-7.49%
1 Year
-13.14%
-13.14%

More News

Read More
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Via Benzinga
Exposures Product Safety
3 Dividend Stocks That Are Screaming Buys in November
Via The Motley Fool
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
Via Benzinga
Topics Government
Exposures Political
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Via Investor's Business Daily
Pfizer Unusual Options Activity For November 20
Via Benzinga
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
Is Biotech’s Bull Run Over? Examining Election Impacts
Via MarketBeat
Topics ETFs Government
Exposures Political
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Via The Motley Fool
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Via Benzinga
Stock Of The Day: Is Pfizer Set Up To Rally?
Via Benzinga
Unpacking the Latest Options Trading Trends in Pfizer
Via Benzinga
Pfizer Announces New Chief Scientific Officer and President, Research & Development
From Pfizer Inc.
Via Business Wire
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Via Benzinga
2 High-Yield Dividend Stocks I Can't Stop Buying
Via The Motley Fool
Not-So-Big Pharma
Via Talk Markets
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Via MarketBeat
Friday's Top 5 Trending Stocks: What's The Scoop On Palantir, Bloom Energy, Pfizer?
Via Benzinga
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
Via Investor's Business Daily
Topics Government
Exposures Political
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.